Abstract:Predicting tumor response after chemoradiotherapy in ESCC remains lacking. This analysis aimed to identify preliminary results of Circulating tumor DNA (ctDNA) markers in predicting tumor response after 4-week chemoradiotherapy for ESCC. We consecutively enrolled patients with unresectable esophageal squamous cell carcinoma, staged as clinical stage III, or clinical stage IV consisting of metastatic lymph nodes in the supraclavicular area according to AJCC 8th. Definitive chemoradiotherapy (CRT) were delivered concurrently with S-1 monotherapy or cisplatin plus paclitaxel-based doublet chemotherapy depending on physician's decision. Plasma samples were collected at different time point if obtained (1) pretreatment (pre-CRT), (2) the 4th week during chemoradiotherapy (mid CRT), (3) 4–8 weeks after chemoradiotherapy (post CRT), (4) 4-6 months in early follow-up time, and (5) disease progression. All patients were subjected to next-generation sequencing (NGS) with a 474 cancer-related gene panel. RECIST and computer tomography (CT) simulation at mid CRT evaluated tumor response. This trial was registered with ClinicalTrials.gov, number NCT0414465. We analyzed 79 serial plasma samples from 37 patients. ctDNA was detectable in 73% (27/37), 46% (12/26) and 31% (5/16) of pretreatment, during chemoradiotherapy and postchemoradiotherapy plasma samples. The most commonly mutated genes in our cohort are TP53 (85.7%, 24/28), CDKN2A (17.9%, 5/28), and ATR (17.9%, 5/28). At diagnosis (pre-CRT), median relative ctDNA abundance was associated with higher clinical T stage (T4 vs T3, 0.76 vs 0.18, p = 0.043). ctDNA concentration was significantly higher with increasing clinical stage (stage IV vs stage III, 109.1 vs 53.4, p = 0.042). Blood-based tumor mutation burden (bTMB) was higher with increasing clinical stage but was not statistically significant. A significant association between ctDNA concentration (r = 0.898, p<0.001) and bTMB (r = 0.737, p<0.001) with relative ctDNA abundance were detected at diagnosis. At mid CRT, overall response rate (ORR) was seen in 67.7% (22/33), including four complete response and 18 partial response. Among 25 patients with both plasma samples and CT evaluation at mid CRT, decreased ctDNA concentration was found in 56% (14/25), increased in 8%, and undetectable ctDNA concentration pre and mid CRT in 36% (9/25). In nine patients with persistently undetectable ctDNA concentration, ORR occurred in 77.8% (7/9). While, in 14 patients with decreased ctDNA concentration, 8 (57%) were associated with ORR. As early assessment, four-week CRT was associated with decreased ctDNA burden. The patients with undetectable ctDNA concentration pretreatment may have a better response to CRT due to relatively lower tumor burden. Radiomics analysis of CT simulation would be used to combine ctDNA assessment in predicting response and prognosis in ESCC. And more enrolled cases with long-term follow-up are needed.

Association of decreased expression of long non-coding RNA LOC285194 with chemoradiotherapy resistance and poor prognosis in esophageal squamous cell carcinoma

Low expression of LOC285194 is associated with poor prognosis in colorectal cancer

Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy

A tumor immune microenvironment-related integrated signature can predict the pathological response and prognosis of esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy: A multicenter study in China

Use of Exosome Transcriptome-Based Analysis to Identify Novel Biomarkers in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemoradiotherapy.

689 MMS22L EXPRESSION AS A PREDICTIVE BIOMARKER FOR THE EFFICACY OF NEOADJUVANT CHEMORADIOTHERAPY IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA

Tumor Remission and Tumor-Infiltrating Lymphocytes During Chemoradiation Therapy: Predictive and Prognostic Markers in Locally Advanced Esophageal Squamous Cell Carcinoma

Gene Expression Analysis of Pretreatment Biopsies Predicts the Pathological Response of Esophageal Squamous Cell Carcinomas to Neo-Chemoradiotherapy

A three‐lncRNA signature of pretreatment biopsies predicts pathological response and outcome in esophageal squamous cell carcinoma with neoadjuvant chemoradiotherapy

Serial Circulating Tumor DNA for Evaluating Early Response During Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: Preliminary Analysis of a Prospective Biomarker Study

Correction For: LncRNA LOC146880 Promotes Esophageal Squamous Cell Carcinoma Progression Via Mir-328-5p/fscn1/mapk Axis

Prognostic and predictive role of COX-2, XRCC1 and RASSF1 expression in patients with esophageal squamous cell carcinoma receiving radiotherapy.

LOC441178 Overexpression Inhibits the Proliferation and Migration of Esophageal Carcinoma Cells via Methylation of miR-182

CT-based Radiomic Analysis for Prediction of Treatment Response of Salvage Chemoradiotherapy for Loco-regional Lymph Node Recurrence After Curative Esophagectomy

A Three-Gene Expression Signature Model to Predict Neo-Chemoradiotherapy Response of Esophageal Squamous Cell Carcinomas.

CAFs-Promoted LncRNA DNM3OS Conferred Radioresistance by Regulating DNA Damage Response in a TNFSF4-Dependent Manner in Esophageal Squamous Cell Carcinoma

Post-radiation circulating tumor DNA as a prognostic factor in locally advanced esophageal squamous cell carcinoma

Analysis of correlation between protein expression of XRCC1 and ERCC1 with efficacy of concurrent radiochemotherapy and the prognosis of patients with esophageal aquamous cell carcinoma

The Role of Folate Receptor-Positive Circulating Tumor Cells in the Prognosis Analysis of Esophageal Squamous Cell Carcinomas.

Prognostic significance of CYFRA21-1, CEA and hemoglobin in patients with esophageal squamous cancer undergoing concurrent chemoradiotherapy.

Computed Tomography-Based Radiomic Analysis for Prediction of Treatment Response to Salvage Chemoradiotherapy for Locoregional Lymph Node Recurrence after Curative Esophagectomy.